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Pulmonary-renal syndromes are a group of disorders characterised by necrotising glomerulo-
nephritis and pulmonary haemorrhage. Small vessel systemic vasculitis is the most common
cause of pulmonary-renal syndromes presenting to respiratory physicians. Rarer causes
include systemic lupus erythematosus and connective tissue diseases though severe pneu-
monia or cardiac failure may mimic their presentation. Some forms of small vessel vasculit-
ides have a predilection for the pulmonary and renal vascular beds and if left untreated can
result in fulminant organ failure. Whilst the aetiology of these syndromes remains unclear,
much is known about the disease mechanisms including the pathogenic role of autoanti-
bodies, immune-complex mediated inflammation and microangiopathic in-situ thrombosis.
Despite established treatments achieving successful remission induction, patient tolerability
and side effect profiles have limited their use which has led to searches for more targeted
treatments. Consequently newer biological therapies have gained wider acceptance despite
little being known about their long term safety and efficacy. The European Vasculitis Study
Group (EUVAS) have recently formulated guidelines to provide consensus on diagnosis and
management in this area and work to define survival rates in these conditions with longer
term follow-up studies is ongoing. This review summarises the current aetiopathogenesistoplasmic antibody; PRS, pulmonary-renal syndromes; GPA, granulomatosis with polyangiitis; CSS,
scopic Polyangiitis; cANCA, cytoplasmic ANCA; pANCA, perinuclear ANCA; PR3, proteinase 3; MPO,
ress: Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, OX 3 7LJ, United Kingdom.
ail.co.uk (C. McCabe), quentinjones7@hotmail.com (Q. Jones), lina.nikolopoulou@gmail.com
kshosp.nhs.uk (C. Wathen), raashid.luqmani@ndorms.ox.ac.uk (R. Luqmani).
Copyright ª 2011 Published by Elsevier Ltd. All rights reserved.
1414 C. McCabe et al.thought to underlie these complex diseases, the diagnostic definitions and classification
criteria currently in use and the evidence base for modern therapies. Though unusual for
respiratory specialists to coordinate overall management of these patients, an update on
their current management is regarded as important to their practice given the recently
changing trends in treatments.
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Pulmonary-renal syndromes (PRS) are defined by the
combination of diffuse alveolar haemorrhage and
glomerulonephritis.1,2 The three most common causes of
PRS presenting to the respiratory physician are ANCA-
positive small vessel vasculitis, anti-glomerular basement
membrane (anti-GBM) disease (Goodpasture’s disease)
and Systemic Lupus Erythematosus (SLE). The ANCA-
positive vasculitides describe three major systemic
syndromes namely granulomatosis with polyangiitis
(Wegener’s) (GPA), Microscopic Polyangiitis (MPA) and
ChurgeStrauss Syndrome (CSS) which between them have
subtle differences in clinical and pathological features.
ANCA-negative vasculitic syndromes such as Henoch
Schonlein Purpura and IgA nephropathy are rarer but may
present in a similar fashion and drug-induced pulmonary-
renal syndromes are also well described.3 Table 1
summarises possible aetiologies. This article aims to
review the presentation, diagnosis and treatment of PRS
with the aim of arming the general respiratory physician
with up to date evidence and research developments in
this complex field.Pathology
The primary pathology in the majority of PRS is inflam-
mation and necrosis of small calibre blood vessels grouped
under the term small vessel vasculitides. Alveolar and
glomerular inflammation arise via neutrophilic infiltration
through vascular endothelium which predominantly
affects arterioles, capillaries and venules. Within the
lung, disruption and degradation of the pulmonary capil-
lary wall and interstitial matrix results in vessel wall
destruction and necrosis. Immune-complex mediated
vasculitis can give rise to an isolated necrotic pulmonary
capillaritis where damaged red blood cells extravasate
directly into alveolar tissue resulting in alveolar
haemorrhage.4
The predominant renal pathological finding in PRS is
necrotising glomerulonephritis.5 Within this there are
multiple pathological variations depending on exact
aetiology. Whilst fibrinoid necrosis and in-situ
microangiopathy are common features, necrotising gran-
ulomata consistent with GPA are rarely seen on renal biopsy
and direct evidence of small vessel vasculitis is uncommon.6
Crescent formation signifies extensive glomerular
Table 1 Causes of pulmonary-renal syndromes.
ANCA-positive vasculitis
e Granulomatosis with polyangiitis (Wegener’s)
e Microscopic Polyangiitis
e ChurgeStrauss syndrome
Anti-glomerular basement membrane antibodies
(Anti-GBM) e Goodpasture’s syndrome
Autoimmune connective tissue disease
e Systemic lupus erythematosus
e Polymyositis
e Scleroderma
ANCA-negative vasculitis
e Henoch Schonlein Purpura
e Mixed cryoglobulinaemia
e IgA nephropathy
e Behcet’s disease
Drug-induced vasculitis e Hydralazine
e Propylthiouracil
e D-penicillamine
Idiopathic pulmonary-renal syndrome
Pulmonary-renal syndromes 1415involvement whereas fibrosis and tubular atrophy are poor
prognostic features. Pauci-immune glomerulonephritis
implies absence of immune-complex deposition, immuno-
globulins or complement within the biopsy sample when
examined using both immunoflourescence and electron
microscopy. This is a feature of the necrotising vasculitis
seen in MPA.
Epidemiology
GPA is a small vessel necrotising vasculitis with an incidence
of 10 cases/million with equal male/female preponder-
ance. It occurs predominantly in Caucasian populations and
presents between the ages of 40 and 55 years in over 70% of
cases.7 Its prognosis has recently been characterised into
a bimodal distribution in mortality with an increased risk of
death from infection, vasculitis and renal failure in the first
year followed by a second peak 8 years from diagnosis
which is so far unexplained.8 A north-south negative
gradient in disease prevalence has been observed across
Europe suggesting a latitude-dependant predisposition and
there are suggestions this finding is reciprocated in the
southern hemisphere.9e11. Studies evaluating occupational
risk for systemic vasculitis have demonstrated a significant
association between farming occupations and silica and
solvent exposure (odds ratio 2.2e2.7) creating aetiological
overlap with other occupational lung diseases such as
hypersensitivity pneumonitis that are commonly encoun-
tered by respiratory physicians.9,12
MPA also causes a necrotising vasculitis and may be
clinically difficult to distinguish from GPA. It has a similar
incidence and mean age of onset around 50 years. As with
GPA, it is more common in Caucasian populations and in its
severest form causes a pauci-immune glomerulonephritiswith alveolar haemorrhage.13 In general pulmonary
involvement occurs in 30e50% of cases whereas renal
involvement extends to over 95% of cases.
CSS is a rare systemic and pulmonary vasculitis with an
incidence of less than 3 cases/million. Though a higher
incidence is quoted in asthmatic populations (64 cases/
million) this may be due to misdiagnosis.14 Males are
affected twice as commonly as females and onset is in
middle-age. It is considered by some to be a three-stage
disease comprising the initial development of asthmatic
symptoms following which a marked blood and tissue
eosinophilia develops. The final stage is a vasculitic phase
which can progress to severe respiratory and renal failure.
Though the aetiology remains unknown, a possible role of
the leukotriene receptor antagonist Montelukast was
postulated15 but this more likely represents a secondary
effect of steroid withdrawal unmasking underlying
vasculitis.16,17 The presence of pANCA, present in 30e50%
of cases, appears to determine a subgroup of patients
predisposed to severe renal disease, pulmonary
haemorrhage and central nervous system involvement.18
Anti-GBM (Goodpasture’s) disease is an even more rare
cause of PRS with an annual incidence of 1 case/million.
Males are four times more likely to be affected with
disease presenting most commonly between 20 and 30
years of age. A second peak in females over 60 appear to
be at increased risk of isolated glomerulonephritis.19
Though smokers are at greater risk of pulmonary hae-
morrhage, Goodpasture’s disease is no more common in
smokers than in non-smokers.20 Familial trends have been
proposed due to strong association with the HLA DR15 and
DR4 alleles21 but most cases occur sporadically suggesting
an important role of other as yet unknown environmental
factors.
SLE presenting as alveolar haemorrhage in the context of
lupus nephritis is extremely rare and carries a grave prog-
nosis with mortality figures between 30% and 50% though
interestingly these figures do not seem to be affected
by the presence or absence of renal failure at
presentation.22e24
Immunology and pathogenesis
ANCA-positive vasculitides
Anti-neutrophil cytoplasmic antibody (ANCA) is an anti-
neutrophil antibody directed against its constituents on
a subcellular level. Although there are a large variety of
ANCA directed against numerous components of the
neutrophil, only two forms of ANCA, specific for proteinase
3 (PR3) and myeloperoxidase (MPO) are thought relevant to
small vessel vasculitis. PR3 and MPO are present in the
azurophilic primary granules of neutrophils and can be
expressed on the cell surface in stimulated poly-
morphonuclear cells. Binding of ANCA to neutrophil
membranes activates the cell leading to the release of lytic
enzymes, chemoattractant interleukin-8 and oxygen free
radicals. Neutrophils subsequently aggregate on endothe-
lium causing inflammation and damage to the vasculature.
The strongest evidence for a pathogenic role of ANCA in
vasculitis comes from a case of a newborn child developing
Table 2 Characteristic clinical findings in PRS.
Purpuric rash
Active urinary sediment on dipstick testing
accompanying biochemical renal impairment
Arthralgia
Cerebral ischaemia
Mononeuritis multiplex
Pericarditis/myocarditis
Sinusitis
Fall in Hb levels
1416 C. McCabe et al.PRS 48 h following delivery from a mother with active MPO-
ANCA MPA via transplacental transfer.25 Despite this it
remains unclear in many diseases whether or not ANCAs are
simply playing a bystander role in the inflammatory cascade
or directly driving vasculitic inflammation.
Characterisation of the precise stimulus for ANCA produc-
tion by B cells is the subject of much ongoing research. It is
well known that chronic inflammatory disorders such as
rheumatoid arthritis, inflammatory bowel disease and auto-
immune hepatitis have a strong association with ANCA posi-
tivity, particularly MPO.26 Hypotheses rooted in the theory of
molecularmimicry have suggested that chronic infectionmay
act as an immunological trigger by bacterial antigens
morphologically imitating neutrophilic peptides leading to
ANCAproduction.27 Staphylococcus aureus colonisationof the
nasal cavity is an established risk factor for disease relapse in
GPA which is thought to result from CpG repeats within
Staphylococcal DNA acting as the antigenic stimulus.28 Else-
where within the respiratory field, chronic suppurative lung
diseases such as cystic fibrosis and bronchiectasis expose
patients to high bacterial burdens for prolonged periods and
there is increasing interest in non-classical target ANCA-
antigen reactivity which may have a pathogenic role in these
diseases. This is perhaps best illustrated by the weak associ-
ation between bactericidal permeability increasing (BPI)-an-
tigen and pseudomonas colonised cystic fibrosis populations
where the presence of BPI-ANCA confers an increased risk of
faster decline in lung functionandpooreroutcomes.29 Further
clarification of the pathogenicity of these autoantigens may
be important to improving our understanding of these
complex multisystem diseases.
Anti-glomerular basement membrane disease:
Goodpasture’s syndrome
Goodpasture’s disease is an antibody mediated (usually IgG)
destruction of the carboxyl terminal of the a-3 chain
of Type IV collagen. This takes place via antibody binding
to peptides in the non-collagenous domain of this
chain which is expressed on numerous vascular beds
including renal glomeruli and tubules, pulmonary alveoli
and retinal capillaries. Variable manifestation of pulmonary
haemorrhage in patients with anti-GBM antibodies may be
due to impaired access of the autoantibody to alveolar
capillary membranes.30,31 Thus patients who have sustained
prior lung injury through smoking, infection or pneumotoxin
inhalation, such as cocaine inhalation, are usually those
most at risk of developing pulmonary haemorrhage or ‘full-
blown’ Goodpasture’s syndrome.31,32 Downstream activa-
tion of complement and proteases destroy the capillary
basement membrane subsequently leading to formation of
crescents in the glomerulus and necrosis of pulmonary
alveolar walls.
Immune-complex mediated disease
The most common cause of immune-complex mediated PRS
is SLE. This is an autoimmune disease characterised by
pathogenic autoantibody production to double stranded
DNA through cognate interactions between B cells and
helper T cells.33 DNA-anti-DNA immune complexes formwithin the glomerulus and activate glomerular complement
leading to cascade production of damaging inflammatory
cytokines and chemoattractants. Persistent inflammation
disrupts the regulated production of damaging transforming
growth factor-beta (TGF-b) leading to pathogenic extra-
cellular matrix deposition in the renal mesangium.34
Essential mixed cryoglobulinaemia (Type II) is another
rare cause of PRS related to immune-complex deposition. It
is thought to be triggered in most cases by chronic Hepatitis
C virus infection.35 Viral antigen stimulates monoclonal
antibody production by B cells leading to an immune-
complex mediated vasculitis resulting in a triad of arthral-
gias, purpura and neurological weakness and in severe
cases alveolar haemorrhage. Henoch Schonlein Purpura,
though more common in younger age groups, can also cause
a pulmonary capillaritis through deposition of IgA immune
complexes within alveoli. Drug-induced vasculitides are
usually ANCA positive (predominantly MPO) and come about
by small molecules forming immune complexes within
capillaries of the pulmonary and renal vasculature. Certain
drugs may act as haptens meaning they elicit immune
responses only when attached to a carrier protein. Common
culprits include hydralazine and propylthiouracil,36 the
former of these exhibiting a dose dependant risk.37
Patient evaluation and clinical features
These disorders exhibit considerable heterogeneity in
clinical presentation both in severity and prognosis. Early
recognition depends on a high index of clinical suspicion
combined with a full assessment of the clinical picture,
available serology, radiology and histology, and exclusion of
alternative diagnoses. Whilst a frequent presentation of
PRS is a patient presenting with breathlessness and fever
with pulmonary infiltrates on a chest radiograph, a signifi-
cant number of patients deteriorate rapidly and present
with life threatening respiratory and/or renal failure
requiring admission to ICU. Initially the diagnosis may not
be clear-cut. Similarities exist with presentation of pneu-
monia or severe cardiac failure with pulmonary oedema but
the presence of some of the abnormalities listed in Table 2
should prompt consideration of PRS to the attending
physician.
Clinically apparent haemoptysis secondary to diffuse
alveolar haemorrhage (DAH) occurs in about 55% of cases.38
In one-third of cases of DAH however, haemoptysis does not
manifest clinically.39 Haemoptysis is usually of small
volume (<200 ml/24 h) and may be accompanied by a low
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Pulmonary-renal syndromes 1417grade fever, breathlessness and cough. Constitutional
symptoms of anorexia and weight loss may be present if
there has been a protracted disease course. Table 3
outlines other clinicopathological features of the most
common disorders.
Acute kidney injury may be apparent from admission
serum biochemistry which carries greater diagnostic
significance in the presence of an active urinary sediment.
Proteinuria is more common than haematuria but when
both are present on urinalysis, this is indicative of
glomerular membrane damage due to glomerulonephritis.
Proteinuria rarely extends to the nephrotic range and an
active urinary sediment in the setting of normal renal
biochemistry does not exclude renal involvement.40 Urine
microscopy may show red cell casts or red cell dysmorphia.
Plain chest radiography or computed tomography of the
chest may reveal a distribution of infiltrates from perihilar
shadowing tending towards the lower zones to frank
consolidation mimicking an ARDS appearance (Figs. 1 and
2). In 25% of cases, chest radiography may be normal in
which event pulmonary thromboembolic disease should be
considered. Cavitating disease is most common in GPA
though diagnostic overlap exists with cavitating pneu-
monia, mycobacterial or malignant disease which in the
acute setting may be difficult to distinguish. Persistence of
interstitial shadowing on plain chest radiograph may
suggest alveolar fluid accumulation secondary to underlying
mitral stenosis, pulmonary veno-occlusive disease or
cardiogenic pulmonary oedema. A rare but important cause
of DAH is idiopathic pulmonary haemosiderosis which may
result in prolonged DAH but renal impairment is not
a feature of this disorder.
Blood test abnormalities may include a normochromic,
normocytic anaemia with elevation of blood nitrogen urea
and creatinine levels. Evidence of haemolysis with frag-
mented red blood cells on film may suggest underlying
thrombotic thrombocytopaenic purpura (TTP). Serum
antibody detection of anti-GBM, ANA and/or ANCA is key
to diagnostic work-up if a PRS is suspected where the
value of a positive result depends chiefly on the pre-test
probability of disease. However the level of ANCA titre is
not considered part of the diagnostic criteria in systemic
vasculitis in the International Consensus Statement of
ANCA testing.41 Whilst the presence of a positive cyto-
plasmic ANCA (cANCA) (directed against PR3 antigen)
correlates with underlying GPA (present in 85% of cases),
perinuclear ANCA (pANCA) (directed against MPO) has
cross reactivity with a number of other inflammatory and
autoimmune conditions, making clinical interpretation
more relevant.
Anti-GBM antibodies detected using different immuno-
assays including immunoperoxidase labelling have a sensi-
tivity of 95e100% with a specificity of 90e100% for
Goodpasture’s disease.31 Anti-GBM disease can exist in the
absence of anti-GBM circulating antibody though its iden-
tification may require testing of patient’s serum with
positive and negative controls to demonstrate reactivity.
Only 35e70% of patients with CSS have a positive cANCA
with 10% being positive for PR3. In fact CSS is more often
ANCA negative than positive, and where positive, usually it
is associated with cANCA or pANCA.
Figure 1 Chest radiograph showing acute pulmonary
haemorrhage.
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onset may show elevation of the gas transfer factor (DLCO).
This is significant if raised by greater than 30%. However
this investigation requires breath-holding on an air, carbon
monoxide and helium mixture for about 10 s. This may not
be possible in those with marked dyspnoea.
Flexible bronchoscopy is generally used in the exclusion
of infection and confirmation of DAH. Classically serial
bronchial washings show increasingly blood stained lavage
fluid and cytology may show haemosiderin-laden macro-
phages adding weight to the diagnosis.
Prior to immunosuppression, confirmation with tissue
diagnosis is often advisable and the kidney and lung
represent the most accessible biopsy sites. In diffuse
pulmonary involvement, thoracoscopic lung biopsy is pref-
erable to transbronchial lung biopsy but this procedure
carries considerable risk. In general, lung biopsy should
only be used as a last resort if the diagnosis cannot be
established in another way.
Percutaneous renal biopsies are often more accessible
and are sent for standard histopathology and immunohis-
tochemistry. GPA classically shows necrotising gran-
ulomata, vascular wall inflammation and geographic
necrosis. CSS in contrast shows extravascular granuloma
with eosinophilic tissue infiltration. Histological confirma-
tion of Goodpasture’s disease requires immunoflourescence
studies with anti-GBM antibody deposition along alveolar
and glomerular basement membrane.PRS in intensive care
A significant number of patients with PRS deteriorate
rapidly and present with life threatening respiratory andFigure 2 CT chest (2 slices) showing diffuse pulmonary
haemorrhage. Both Figs. 1 and 2 reproduced with permission.renal failure requiring admission to ICU. Their management
represents a major challenge as mortality is of the order of
25e50%. If left untreated, PRS can follow a fulminant
course and is often fatal.42 As with more indolent presen-
tations, outcome depends on prompt recognition, exclusion
of infection and rapid aggressive treatment. Transfer to
a specialist centre may be needed.
Diagnosis in the ICU
In the majority of patients admitted to ICU the diagnosis is
already known.42 Acute deterioration may be due to a flare
of the underlying disease causing diffuse alveolar haemor-
rhage (DAH) and respiratory failure or more commonly
severe infection or drug toxicity caused by immunosup-
pressive treatment. In some patients, the diagnosis is made
only after admission to ICU. In a series of 26 patients
admitted to ICU with systemic necrotising vasculitis,
a surprising high number (42%) were diagnosed in the ICU.43
Diagnosis of pulmonary-renal syndrome in the ICU can be
challenging. There is no single test and premorbid symp-
toms and signs are often non-specific. There is considerable
overlap with other common ICU presentations such as sepsis
and cardiorespiratory compromise. A history of breath-
lessness and cough with low grade fever should be sought
which has subsequently developed into clinical respiratory
failure with non-specific changes on the chest radiograph.
Even in severely unwell patients haemoptysis is frequently
absent despite radiological suggestion of DAH.
Pointers to vasculitis in critically ill patients are as
previously discussed. Worsening pulmonary infiltrates
with persistent low grade fever in the face of falling hae-
moglobin and renal failure requiring haemofiltration is
suggestive of PRS. The presence of blood and protein in the
urine rather than leukocytes and nitrites may have led to
treatment for urosepsis rather than prompting a search for
glomerulonephritis. New onset hypertension can herald
undiagnosed renal involvement and unexplained hypoxia
may indicate subclinical pulmonary haemorrhage especially
in the context of progressive coalescing alveolar shadowing
on chest radiography.
Distinguishing vasculitis from infection in the ICU setting
is essential. Persistently negative microbiological samples,
in the context of an inflammatory illness, make the pres-
ence of vasculitis more likely. When safe to do so, bron-
choscopy should be performed to exclude infection and
look for evidence of DAH.
Intensive care unit specific management
In the ICU the management of pulmonary-renal syndromes
centres on immunosuppression therapy (outlined later) and
supportive care. Some important aspects of supportive care
are listed below:
Minimizing the risk of sepsis
Patients with vasculitis frequently die of sepsis.43 In a series
of 26 patients with necrotising vasculitis admitted to ICU,
75% died of sepsis.44 The risk of nosocomial infection in
Pulmonary-renal syndromes 1419these patients is very high due to immune-suppression.
Severe infection due to cyclophosphamide occurs in about
10% of cases and has a high mortality.42 Careful monitoring
for bone marrow suppression and superadded infection is
indicated. Septrin prophylaxis against PCP infection is often
used.
Respiratory and airway management
In GPA there may be subglottic stenosis which can result in
difficult intubation. Smaller endo-tracheal tubes or
tracheostomy may be needed.42 In acute lung injury due to
diffuse alveolar haemorrhage large tidal volumes or pres-
sure changes may exacerbate damage to pulmonary
microvasculature. Lung protective ventilation, as used in
the management of ARDS, with tidal volumes of 6 ml/kg and
inspiratory plateau pressures below 30 cmH2O with
permissive hypercapnia may reduce lung injury.42
Cardiovascular and renal
Patients with pulmonary-renal syndrome may be hypoten-
sive because of a combination of dehydration, haemorrhage
and systemic inflammatory response and may require
inotropic support. Many patients develop severe acute
renal failure and require haemodialysis in ICU. Of these the
majority will eventually progress to end stage renal failure
and require long term renal replacement therapy.
Treatments
ANCA associated PRS: remission induction
Treatment outcomes for systemic vasculitis prior to the
introduction of glucocorticoids were dismal with survival at
1 year from diagnosis in the region of 20e30%.45 This
benefit disappeared at 3 years most probably secondary to
complications from long term steroids. The introduction of
cyclophosphamide in conjunction with steroids in the 1970s
heralded a new age in vasculitis management in that 5-year
mortality was lowered from 50% with glucocorticoid treat-
ment alone to 12% with combination therapy.46
Cyclophosphamide is an alkylating agent that brings
about cell apoptosis through DNA and RNA synthesis inhi-
bition. Its side effect profile depends on cumulative dose.
Acutely it predisposes to haemorrhagic cystitis and myelo-
suppression. Chronically it increases the lifetime risk of
bladder cancer, lymphoproliferative disorders and gonadal
toxicity. Despite this advance, treatment toxicities and
secondary complications remain relatively frequent and
survival curves are still attenuated compared to the normal
population. Age and serum creatinine at presentation
remain the strongest predictors of both survival and renal
outcome.47
Induction of remission is most commonly achieved with
high dose intravenous methyprednisolone (0.5 ge1 g/day)
for 3e5 days for which there is no substantial evidence
base. This is coupled with pulsed intravenous cyclophos-
phamide administered every 2e3 weeks (15 mg/kg/pulse)
on 6e9 occasions or as a daily oral regime (1e2 mg/kg/day). In the presence of severe renal disease defined as
a serum creatinine >500 mmol/L, there is additional short
term benefit from plasmapheresis in terms of renal
recovery in the first 18 months.
Debate continues over the long term benefit of plasma
exchange (PE) in the acute setting. The mechanism of
action of PE is largely unknown. PE is likely to dilute down
ANCA titres and removes a large fraction of pro-
inflammatory cytokines, complement and coagulation
factors from the systemic circulation. It most likely
decreases progression to end stage renal disease in those
with severe renal failure at presentation.48 There is no
proven long term survival benefit from its use and
furthermore little evidence for its role in the treatment of
less severe disease. Other agents used less frequently for
induction of remission include methotrexate and myco-
phenolate mofetil (MMF). Whilst methotrexate is contra-
indicated in severe renal disease, MMF has shown
superiority to cyclophosphamide in maintaining normal
renal function at 6 months from diagnosis.49 A recent trial
of rituximab for induction of remission in ANCA associated
disease was not superior to standard intravenous cyclo-
phosphamide. Sustained-remission rates were high in both
groups however.50
Maintenance of remission
The most effective method of maintenance of remission
is also the subject of ongoing trials and there is
considerable inter-practitioner variability over both choice
of immunosuppression and duration of treatment.
Currently, glucocorticoids are continued at low dose for
a minimum of 18 months alongside a steroid sparing agent.
This is usually extended to 2 years total in those with PR3
positive ANCA in view of their higher rate of relapse.51 The
most widespread European practice is switching from
cyclophosphamide to azathioprine at the 3e6 month
interval from diagnosis.
Studies looking at maintenance therapy with metho-
trexate, leflunomide and MMF have not shown any advan-
tage over azathioprine to date.52e54 Biological therapies
studied include the TNF-a inhibitor Infliximab and the TNF-
a receptor protein Etanercept. These along with Rituximab,
which is an anti-CD20 antibody that depletes B cells,
initially looked promising candidates for remission induc-
tion. Both anti-TNF-a agents tested however resulted in
unacceptably high infection complication rates.55,56 Ritux-
imab has however recently been demonstrated to be as
effective as cyclophosphamide in two randomised
controlled trials.50,57
Anti-glomerular basement membrane disease e
Goodpasture’s
Urgent plasma exchange is initiated when this diagnosis is
suspected to deplete plasma of circulating anti-GBM anti-
body. There is evidence to suggest earlier commencement
has beneficial effect on long term renal recovery.58 On
average a 14-day course of plasma exchange is completed
which is usually adequate to return anti-GBM antibody to
normal titres. Immunosuppression is started alongside this
1420 C. McCabe et al.therapy usually consisting of oral prednisolone (1 mg/kg)
and oral cyclophosphamide (2e3 mg/kg/day). Available
evidence suggests completely anuric patients respond
poorly to this regime going on to require long term renal
replacement therapy with consequent poor survival in the
region of 50% at 2 years.58
Systemic lupus erythematosus
Pulmonary haemorrhage in the context of lupus nephritis
carries a poor prognosis. Urgent immunosuppression should
be given with high dose methylprednisolone and cyclo-
phosphamide. New therapies such as Rituximab and MMF
are in trial stages which bring about successful remission in
80% of cases.59,60 Relapse rates are high however despite
the improved toxicity profile.60 Recent studies looking at
rituximab as add-on therapy in SLE have failed to show
significant benefit but this is most likely due to poor trial
design.61,62
Conclusion
Our rationale for review of these rare disorders is their
frequent first presentation to respiratory physicians and
disproportionate lack of involvement in subsequent care.
Clinical vigilance is key as the symptom complex of PRS is
often non-specific. The diversity of conditions encompassed
by this group of disorders lends itself to a wide range of
severity of presentation from the general outpatient clinic
to the ICU setting. Often multidisciplinary input is required.
Although traditionally the domain of our rheumatology and
renal colleagues, an updated working knowledge of PRS
including the disease pathogenesis and complications is
central to the practice of a general respiratory physician
especially in such a rapidly advancing field with increasingly
targeted treatment strategies.
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